CYTOSINE-ARABINOSIDE AND CISPLATIN FOR ADVANCED BREAST-CANCER - A PHASE-II STUDY OF THE CANCER AND LEUKEMIA GROUP-B

被引：0

作者：

OSTER, MW

SCHILSKY, RL

FARAGGI, D

KORZUN, AH

PERRY, M

MOORE, A

KALRA, J

WOOD, WC

HENDERSON, IC

机构：

[1] LONG ISL JEWISH MED CTR,NEW HYDE PK,NY

[2] COLUMBIA UNIV COLL PHYS & SURG,NEW YORK,NY 10032

[3] CORNELL UNIV,MED CTR,COLL MED,NEW YORK,NY 10021

[4] UNIV CHICAGO,PRITZKER SCH MED,CHICAGO,IL 60637

[5] HARVARD UNIV,SCH PUBL HLTH,BOSTON,MA 02115

[6] HARVARD UNIV,SCH MED,BOSTON,MA 02115

[7] UNIV MISSOURI,MED CTR,SCH MED,COLUMBIA,MO 65201

来源：

CANCER | 1991年 / 68卷 / 08期

关键词：

D O I：

10.1002/1097-0142(19911015)68:8<1696::AID-CNCR2820680807>3.0.CO;2-B

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Forty-four women with advanced breast cancer participated in a prospective clinical trial to evaluate the efficacy and toxicity of a regimen consisting of cytosine arabinoside and cisplatin. All patients had previously received chemotherapy. Three patients (7%) responded to therapy with response durations of 153, 160, and 441 days. The median time to disease progression and median survival time in all 44 patients were 2.3 and 5 months, respectively. This regimen had significant toxicity, with most patients experiencing severe or life-threatening hematologic, renal, or infectious complications. This regimen cannot be recommended for previously treated patients with advanced breast cancer.

引用

页码：1696 / 1698

页数：3

共 50 条

[31] TREATMENT OF PRIMARY OR METASTATIC PLEURAL EFFUSION WITH INTRACAVITARY CYTOSINE-ARABINOSIDE AND CISPLATIN - A PHASE-II STUDY
AITINI, E
CAVAZZINI, G
PASQUINI, E
RABBI, C
COLOMBO, F
CANTORE, M
FATTORI, PP
PARI, F
BERTUZZI, A
SMERIERI, F
ACTA ONCOLOGICA, 1994, 33 (02) : 191 - 194
[32] RANDOMIZED PHASE-II TRIAL OF CISPLATIN WITH MITOMYCIN OR DOXORUBICIN FOR MALIGNANT MESOTHELIOMA BY THE CANCER AND LEUKEMIA GROUP-B
CHAHINIAN, AP
ANTMAN, K
GOUTSOU, M
CORSON, JM
SUZUKI, Y
MODEAS, C
HERNDON, JE
AISNER, J
ELLISON, RR
LEONE, L
VOGELZANG, NJ
GREEN, MR
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (08) : 1559 - 1565
[33] PHASE-II TRIAL OF AMSACRINE IN PATIENTS WITH HEPATOMA - A CANCER AND LEUKEMIA GROUP-B STUDY
AMREIN, PC
RICHARDS, F
COLEMAN, M
POULIN, RF
HOLLAND, JF
WEINBERG, V
PERRY, M
CANCER TREATMENT REPORTS, 1984, 68 (06): : 923 - 924
[34] VINDESINE - A PHASE-II STUDY IN CHILDHOOD MALIGNANCIES - A REPORT FOR CANCER AND LEUKEMIA GROUP-B
ETTINGER, LJ
BRECHER, M
COLEMAN, M
SMITHSON, WA
PATTERSON, R
RUSSELL, EC
NECHELES, T
JONES, B
OHNUMA, T
MEDICAL AND PEDIATRIC ONCOLOGY, 1982, 10 (01): : 35 - 43
[35] A PHASE-II STUDY OF CISPLATIN AND CYTOSINE-ARABINOSIDE FOR RECURRENT SQUAMOUS-CELL CARCINOMA OF THE HEAD AND NECK
BERNSTEIN, JI
JACOBS, C
MEYERS, F
RICHGOFFINET, L
TANAKA, L
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1986, 9 (01): : 58 - 60
[36] ELLIPTINIUM - PHASE-II STUDY IN ADVANCED MEASURABLE BREAST-CANCER
TREAT, J
GREENSPAN, A
RAHMAN, A
MCCABE, MS
BYRNE, PJ
INVESTIGATIONAL NEW DRUGS, 1989, 7 (2-3) : 231 - 234
[37] CARMINOMYCIN VERSUS DOXORUBICIN IN ADVANCED BREAST-CANCER, A RANDOMIZED PHASE-II STUDY OF THE EORTC BREAST-CANCER COOPERATIVE GROUP
VANOOSTEROM, AT
MOURIDSEN, HT
WILDIERS, J
PARIDAENS, R
COCCONI, G
ROTMENSZ, N
SYLVESTER, R
EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1986, 22 (05): : 601 - 605
[38] PHASE-II STUDY OF VINDESINE IN PATIENTS WITH ADVANCED BREAST-CANCER
WALKER, BK
RAICH, PC
FONTANA, J
SUBRAMANIAN, VP
ROGERS, JS
KNOST, JA
DENNING, B
CANCER TREATMENT REPORTS, 1982, 66 (09): : 1729 - 1732
[39] A PHASE-II STUDY OF DOXIFLURIDINE IN PATIENTS WITH ADVANCED BREAST-CANCER
ALBERTO, P
JUNGI, WF
SIEGENTHALER, P
MERMILLOD, B
OBRECHT, JP
DECOSTER, G
CAVALLI, F
EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1988, 24 (03): : 565 - 566
[40] LYMPHOBLASTOID INTERFERON IN ADVANCED BREAST-CANCER - A PHASE-II STUDY
NASO, C
SIMONI, C
MERLINI, L
ROSSO, M
PRONZATO, P
REPETTO, L
GARDIN, G
ROSSO, R
JOURNAL OF CHEMOTHERAPY, 1993, 5 (04) : 258 - 261

← 1 2 3 4 5 →